SteadyMed Ltd. (NASDAQ:STDY) is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company`s lead candidate is Trevyent, a development stage drug product that utilizes SteadyMed`s PatchPump technology to administer treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension. PatchPump is a proprietary, disposable, parenteral drug administration platform that is prefilled and preprogrammed at the site of manufacture. SteadyMed has offices in San Ramon, California and Rehovot, Israel.
- The market for Biologic drugs, drugs that need to be injected or infused, is continuously growing.
- The current global Biologic drug market is valued at $120 billion.
- Current injection technologies can deliver only small dosages and low viscosity drugs, thus addressing only half of the biologic drugs market potential.